Mireille Kielemoes

Mireille Kielemoes is Managing Director of Fund Investments at BNP Paribas Fortis Private Equity, the private-equity arm of Belgium's largest bank. She has 15+ years of experience in fund investing, and served as Managing Director at BNP Paribas Fortis Private Equity Belgium NV from roughly 2010 to 2022; she is currently listed as a director of BNP Paribas Fortis Private Equity Expansion NV and BNP Paribas Fortis Private Equity Management NV. Within the firm she leads the "Fund Investments" (fund-of-funds / LP) practice, which sits alongside the separate "Direct Investments" team headed by Raf Moons.

Her work centers on selecting and committing the bank's capital as a limited partner into venture-capital and private-equity funds, and on representing BNP Paribas Fortis on the advisory boards and strategic committees of those funds. Reported advisory/board memberships include Fortino, LSP Health Economics Fund (LSP HEF), SmartFin, Sofindev, several university-linked funds, and Quality Assistance — spanning tech, life sciences and diversified growth strategies.

Beyond her role at the bank, Kielemoes chairs Private Capital Belgium (formerly the BVA — the Belgian Venture Capital & Private Equity Association), the professional body representing Belgium's VC and PE community (founded 1986). She succeeded Renaat Berckmoes as chair and serves alongside board members including Jan Alexander, Hilde Vandermeulen and Jette de Koning. She has also been active in industry education, sharing her experience investing in VC and PE funds through programs such as the BVA/Private Capital Belgium "LP Academy."

She is a frequent public spokesperson for BNP Paribas Fortis on its fund commitments, quoted in announcements about the Belgian Growth Fund, imec.xpand, Jeito Capital and ForsVC. She is based in the Ghent area of Belgium.

• Invests as an LP / fund-of-funds — deploying BNP Paribas Fortis's balance sheet into carefully selected VC and PE funds rather than making direct angel/startup investments.
• Anchors on innovation and entrepreneurship: she framed the imec.xpand deep-tech commitment as fitting "perfectly within the Bank's investment strategy in the area of innovation and entrepreneurship."
• Strong tilt toward deep tech / nanotechnology (imec.xpand — healthcare, smart cities, mobility, logistics, energy, Industry 4.0) and toward life sciences / biotech.
• On healthcare/biotech, she values managers that shorten development timelines: on Jeito Capital she highlighted that a continuous-funding model "cut[s] the development time needed by a biotech company, by removing the time needed for fundraising," aligning ~15-year drug-development horizons with fund economics.
• Backs Belgium-rooted growth: via the Belgian Growth Fund (a fund-of-funds) she supports "promising Belgian companies to achieve national and international growth while remaining Belgium-based."
• Willing to seed new, niche fund strategies — e.g. co-founding ForsVC to build a domestic financing base for the Belgian video-game industry and counter brain drain.
• Looks for funds with a societal-impact dimension and experienced, often diverse management teams (she noted Jeito's notably female-led team).